Commentary|Articles|September 2, 2026

Eichenbaum: KSI-101 could become first-line in uveitic macular edema

Author(s)Kassi Filkins, David A. Eichenbaum, MD, FASRS

Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.

Macular edema secondary to non-infectious inflammation (MESI) remains one of the more difficult presentations in the retina clinic, where treatment still leans heavily on corticosteroids and their well-known cataract and intraocular pressure trade-offs; additionally, no intravitreal biologic is yet FDA-approved specifically for the indication.